Merck offers discounted, cash-generative exposure to a $70 billion pipeline, but its 2028–2029 Keytruda cliff makes Qlex execution and M&A outcomes decisive.
Overview
Merck & Co. is a diversified global biopharmaceutical company whose Pharmaceutical segment supplies the majority of revenue, complemented by Animal Health. Its principal competitive advantages are extensive clinical evidence, broad regulatory labels, physician switching costs, manufacturing scale and patent protection. The United States generated $36.51 billion, or 56.16% of FY2025 sales, while total FY2025 revenue reached $65.01 billion. **The central investment issue is the 2028–2029 Keytruda patent cliff:** Keytruda contributes approximately 55% of pharmaceutical sales, making successful conversion to Keytruda Qlex and replacement-product launches critical. The underlying business remains resilient: Q1 2026 revenue was $16.29 billion, 5% nominal growth, and exceeded consensus by 2.52%, while non-GAAP EPS loss of $1.28 beat expectations despite a $9.0 billion Cidara-related charge. Winrevair reached $525 million and Ohtuvayre $131 million in Q1 sales, but Gardasil declined 19% and Januvia/Janumet declined 28%. Merck trades at 13.52x forward P/E versus a 19.42x healthcare average. Near-term catalysts include Keytruda and Welireg regulatory decisions, pipeline readouts, Terns integration and Chinese Gardasil inventory stabilization. The report views the shares as an undervalued, income-oriented transitional opportunity rather than a low-risk compounder.